Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor and Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT00903968Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2009
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of plerixafor in multiple myeloma (MM) (8 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Plerixafor Maximum Tolerated Dose at 21 days, Bortezomib Maximum Tolerated Dose at 21 days and 2 more. Started Jun 2009; status: completed.
02
Drugs
plerixafor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00903968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00903968.